All In Biotech

Drug Trial Radar · NCT04656600

Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ

A Single Arm, Prospective, Open Label, Multicenter Study to Evaluate Efficacy and Safety of One-year Maximum Dosage in Chinese Label of Imiglucerase Treatment in Chinese Patients Who Are Diagnosed as Gaucher Disease Type Ⅲ

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Mar 2, 2021

Primary completion

Oct 12, 2023

Study completion Oct 12, 2023

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective * To evaluate the efficacy on hematologic manifestations of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the safety profile of imiglucerase in maximum dose in the label (60U/kg, IV biweekly) in Chinese patients. Secondary Objective * To evaluate the efficacy on viscera manifestations of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the efficacy on bone disease of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ * To evaluate the effect on quality of life of imiglucerase treatment in Chinese patients who are diagnosed as Gaucher disease type Ⅲ

Conditions

  • Gaucher's Disease

Interventions

  • Cerezyme® / ImigluceraseDrug

    Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in haemoglobinTime frame: Baseline to the end of 12 months
  2. Changes in platelet countTime frame: Baseline to the end of 12 months
  3. Adverse eventsTime frame: Baseline to the end of 13 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 107

    Beijing, China

  • Investigational Site Number : 101

    Beijing, China

  • Investigational Site Number : 104

    Chengdu, China

  • Investigational Site Number : 102

    Guangzhou, China

  • Investigational Site Number : 105

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.